Form 10-Q Calithera Biosciences, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share
November 10, 2015 9:43 AM ESTCalithera Biosciences (NASDAQ: CALA) reported Q3 EPS of ($0.49), versus ($16.85) reported last year.
Anticipated Upcoming Milestones
Hematologic Phase 1 clinical trial data by year end 2015Initiation of six CB-839 combination expansion cohorts by year end 2015CB-839 combination therapy data in... MoreCalithera Biosciences (CALA) Files $150M Common Stock Shelf
November 10, 2015 9:41 AM ESTCalithera Biosciences (NASDAQ: CALA) filed a registration with the U.S. SEC to sell up to $150 million worth of common stock.
... More